The ultra?long?acting multispecific antibody platform integrates AI?assisted VHH discovery, developability optimization, and mismatch?free assembly to achieve long?acting multispecific antibodies at high concentrations. This enables subcutaneous dosing every ≥3 months, delivering synergistic or complementary multi?target effects and significantly improving patient compliance.